Department of General Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA.
Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Ann Surg Oncol. 2023 Oct;30(10):5990-5996. doi: 10.1245/s10434-023-13888-4. Epub 2023 Aug 11.
Alternative service delivery models are critically needed to address the increasing demand for genetics services and limited supply of genetics experts available to provide pre-test counseling.
We conducted a prospective randomized controlled trial of women with stage 0-III breast cancer not meeting National Comprehensive Cancer Network (NCCN) criteria for genetic testing. Patients were randomized to pre-test counseling with a Chatbot or a certified genetic counselor (GC). Participants completed a questionnaire assessing their knowledge of breast cancer genetics and a survey assessing satisfaction with their decision regarding pre-test counseling.
A total of 39 patients were enrolled and 37 were randomized to genetic counseling with an automated Chatbot or a GC; 19 were randomized to Chatbot and 18 to traditional genetic counseling, and 13 (38.2%) had a family member with breast cancer but did not meet NCCN criteria. All patients opted to undergo genetic testing. Testing revealed six pathogenic variants in five patients (13.5%): CHEK2 (n = 2), MSH3 (n = 1), MUTYH (n = 1), and BRCA1 and HOXB13 (n = 1). No patients had a delay in time-to-treatment due to genetic testing turnaround time, nor did any patients undergo additional risk reducing surgery. There was no significant difference in median knowledge score between Chatbot and traditional counseling (11 vs. 12, p = 0.09) or in median patient satisfaction score (30 vs. 30, p = 0.19).
Satisfaction and comprehension in patients with breast cancer undergoing pre-test genetic counseling using an automated Chatbot is comparable to in-person genetic testing. Utilization of this technology can offer improved access to care and a much-needed alternative for pre-test counseling.
为满足对遗传服务日益增长的需求,同时应对可提供检测前咨询的遗传专家人数有限这一现状,迫切需要替代服务交付模式。
我们对不符合国家综合癌症网络(NCCN)基因检测标准的 0-III 期乳腺癌女性患者进行了一项前瞻性随机对照试验。患者被随机分配至使用聊天机器人或经认证遗传咨询师(GC)进行检测前咨询。参与者完成了一份评估其乳腺癌遗传学知识的问卷和一份评估其对检测前咨询决策满意度的调查。
共纳入 39 例患者,37 例患者被随机分配至遗传咨询,包括使用自动化聊天机器人或 GC;19 例被随机分配至聊天机器人组,18 例被随机分配至传统遗传咨询组,其中 13 例(38.2%)有乳腺癌家族史但不符合 NCCN 标准。所有患者均选择进行基因检测。检测结果显示 5 例患者(13.5%)存在 6 种致病性变异:CHEK2(n=2)、MSH3(n=1)、MUTYH(n=1)和 BRCA1、HOXB13(n=1)。没有患者因基因检测周转时间而延迟治疗,也没有患者进行额外的降低风险手术。聊天机器人组和传统咨询组的知识评分中位数(11 分比 12 分,p=0.09)或患者满意度评分中位数(30 分比 30 分,p=0.19)均无显著差异。
使用自动化聊天机器人进行检测前遗传咨询的乳腺癌患者的满意度和理解程度与面对面遗传咨询相当。这种技术的应用可以提供更好的获得护理的机会,并为检测前咨询提供急需的替代方案。